| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/22/2013 | WO2013122988A1 Amorphous medicinal fine particles produced by pulsed laser ablation in liquid and the production method thereof |
| 08/22/2013 | WO2013122801A1 Ophthalmic pharmaceutical compositions and methods of making and using same |
| 08/22/2013 | WO2013122642A2 D, l-cyclic peptide nanotube reinforcing agents |
| 08/22/2013 | WO2013122621A1 Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
| 08/22/2013 | WO2013122620A1 Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels |
| 08/22/2013 | WO2013122559A1 Composition and methods for quenching free radicals and modulating inflammation |
| 08/22/2013 | WO2013122554A1 Pellet formulations comprising esomeprazole |
| 08/22/2013 | WO2013122553A1 A pharmaceutical formulation comprising an atp-ase inhibitor and method for this formulation |
| 08/22/2013 | WO2013122446A1 Composition for preventing tachycardia during heart pain treatment |
| 08/22/2013 | WO2013122413A1 Oral formulation comprising lansoprazole and the preparation method thereof |
| 08/22/2013 | WO2013122260A1 Tablet |
| 08/22/2013 | WO2013121452A1 Product comprising glucomannan and chitosan for the treatment gastroesophageal reflux disease |
| 08/22/2013 | WO2013121429A1 Formulations and kits for forming bioadhesive matrices |
| 08/22/2013 | WO2013121354A1 Oil-based pharmaceutical composition for the treatment of gastrointestinal diseases |
| 08/22/2013 | WO2013121296A1 Erythrocyte-binding therapeutics |
| 08/22/2013 | WO2013121233A1 Pharmaceutical formulation having improved stability |
| 08/22/2013 | WO2013121184A1 Hydrocortisone controlled release formulation |
| 08/22/2013 | WO2013120888A2 Core sheath drug delivery devices |
| 08/22/2013 | WO2013120881A1 Method for treating intestinal diseases presenting at least one inflammatory component |
| 08/22/2013 | WO2013120856A1 Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof |
| 08/22/2013 | WO2013120463A1 A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
| 08/22/2013 | WO2013120229A1 METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS |
| 08/22/2013 | WO2013120184A1 Ingestible medical device |
| 08/22/2013 | WO2013100585A3 Adonis amurensis extract or anti-cancer composition using same as an active ingredient |
| 08/22/2013 | WO2013098268A3 Tablets and dry-coated agents |
| 08/22/2013 | WO2013090861A8 Alpha-aminoamidine polymers and uses thereof |
| 08/22/2013 | WO2013067199A3 Subcutaneous delivery of polymer conjugates of therapeutic agents |
| 08/22/2013 | WO2013066214A3 Aerosol pharmaceutical composition of protease inhibitors and production thereof |
| 08/22/2013 | WO2012091593A8 Granulates comprising eslicarbazepine acetate |
| 08/22/2013 | WO2012035283A8 Pharmaceutical composition |
| 08/22/2013 | US20130217786 Porous nanostructures and methods involving the same |
| 08/22/2013 | US20130217777 Process for making multiparticulate gastroretentive dosage forms |
| 08/22/2013 | US20130217772 Ibuprofen intravenous infusion |
| 08/22/2013 | US20130217769 Pharmaceutical semi-solid composition of isotretinoin |
| 08/22/2013 | US20130217741 Topical pharmaceutical compositions for treatment of skin damage |
| 08/22/2013 | US20130217716 Pharmaceutical Formulation Containing Gelling Agent |
| 08/22/2013 | US20130217621 Compositions for the treatment of diabetes |
| 08/22/2013 | US20130217620 Ionic silicone hydrogels |
| 08/22/2013 | US20130217129 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130217069 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130216624 Sustained-release pellets containing tacrolimus as an active ingredient |
| 08/22/2013 | US20130216623 Apparatus and formulations for suprachoridal drug delivery |
| 08/22/2013 | US20130216620 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 08/22/2013 | US20130216619 Pharmaceutical composition of atorvastatin and ezetimibe |
| 08/22/2013 | US20130216618 Soft capsule based on starch and a method and device for the production thereof |
| 08/22/2013 | US20130216617 Pharmaceutical compositions of (r)-lansoprazole |
| 08/22/2013 | US20130216616 Customized polypills having high drug loads |
| 08/22/2013 | US20130216612 Targeted intracellular delivery of antiviral agents |
| 08/22/2013 | US20130216610 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
| 08/22/2013 | US20130216607 Zwitterionic lipids |
| 08/22/2013 | US20130216606 Liposomal formulation for ocular drug delivery |
| 08/22/2013 | US20130216604 Polypeptide for inhibiting metastasis, uses thereof, and pharmaceutical compositions containing the same |
| 08/22/2013 | US20130216603 Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
| 08/22/2013 | US20130216602 Clonidine compounds in a biodegradable polymer |
| 08/22/2013 | US20130216596 Nanocapsules containing microemulsions |
| 08/22/2013 | US20130216594 Preparation of orodispersible films |
| 08/22/2013 | US20130216593 Systems, methods, and devices for plasmid gene transfection using polymer-modified microbubbles |
| 08/22/2013 | US20130216592 Particles consisting of a chitosan polyelectrolyte complex and of an anionic polysaccharide, and having improved stability |
| 08/22/2013 | US20130216590 Topical antiviral formulations for prevention of transmission of hsv-2 |
| 08/22/2013 | US20130216589 Oral vaccine for aquatic animals |
| 08/22/2013 | US20130216588 Insulin-gold nanocluster, pharmaceutical composition for reducing blood glucose comprising the same, and method for detecting adipose cells in tissue by using the same |
| 08/22/2013 | US20130216532 Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof |
| 08/22/2013 | US20130216525 Concentrated protein formulations and uses thereof |
| 08/22/2013 | US20130216512 Stable aqueous suspension |
| 08/22/2013 | US20130216499 Compositions of recombinant human endostatin adenovirus injections and methods of production |
| 08/22/2013 | US20130216484 Bioenzymatic tablet |
| 08/22/2013 | US20130216483 Delivery system for remote treatment of an animal |
| 08/22/2013 | US20130216474 Nanocells for diagnosis and treatment of diseases and disorders |
| 08/21/2013 | EP2628531A2 Method for the polymeric encapsulation of intercalation compounds composed of lamellar solids and dyes |
| 08/21/2013 | EP2628506A1 Antimicrobially active composition having a content of bispyridinium alkane (octenidine dihydrochloride) |
| 08/21/2013 | EP2628488A1 Sustained-release pharmaceutical composition |
| 08/21/2013 | EP2628484A1 Platelet-rich plasma compositions |
| 08/21/2013 | EP2628483A1 Medical adsorbent and method for producing same |
| 08/21/2013 | EP2627676A1 Novel cellulose ethers and their use |
| 08/21/2013 | EP2627335A1 Composition for skin treatment |
| 08/21/2013 | EP2627325A1 Pharmaceutical composition |
| 08/21/2013 | EP2627320A1 Formulation comprising a type b lantibiotic |
| 08/21/2013 | EP2627319A1 Pharmaceutical compositions containing a dgat1 inhibitor |
| 08/21/2013 | EP2627318A2 Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| 08/21/2013 | EP2627317A2 Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
| 08/21/2013 | EP2627316A1 Pharmaceutical formulation for histone deacetylase inhibitors |
| 08/21/2013 | EP2627315A1 Composition for treating cancer by the controlled release of an active substance |
| 08/21/2013 | EP2627314A1 Non-starch based soft chewables |
| 08/21/2013 | EP2627313A2 Phosphate binder formulation for simple ingestion |
| 08/21/2013 | EP2627309A2 Use of monoamine oxidase inhibitors to improve epithelial biology |
| 08/21/2013 | EP2627302A1 Suction device |
| 08/21/2013 | EP2627284A2 Apparatuses and methods of intravaginal support and/or distension |
| 08/21/2013 | EP2627173A1 Clevidipine emulsion formulations containing antimicrobial agents |
| 08/21/2013 | CN203139147U Self-conformal anti-seepage mirabilite paste |
| 08/21/2013 | CN203139146U Slow-release annular bi-colour tablet |
| 08/21/2013 | CN203139145U Annular bi-colour tablet |
| 08/21/2013 | CN203138850U Rhinitis paste for kids |
| 08/21/2013 | CN103261404A Dry granulated cell culture media |
| 08/21/2013 | CN103261233A Novel cellulose ethers and their use |
| 08/21/2013 | CN103260702A A sustained release formulation of a non-steroidal anti-inflammatory drug |
| 08/21/2013 | CN103260635A Compositions and uses of materials with high antimicrobial activity and low toxicity |
| 08/21/2013 | CN103260617A Novel pharmaceutical formulation comprising NSAID and cyclodextrin |
| 08/21/2013 | CN103260616A Stabilizer of acetaminophen |
| 08/21/2013 | CN103260615A Low dose pharmaceutical composition |
| 08/21/2013 | CN103260611A Low molecular weight cationic lipids for oligonucleotide delivery |